Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 5/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27985789 | 0.75 | EPHX1 (0.46) | EPHX1PDE2AALDH1A1EPHX2TRPV1 | |
| SCHEMBL27985776 | 0.75 | EPHX1 (0.40) | EPHX1PDE2ASLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL19946345 | 0.74 | EPHX1 (0.42) | EPHX1PDE2ASLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL27986122 | 0.74 | SLC6A2 (0.44) | EPHX1SLC6A4SLC6A2ALDH1A1EPHX2 | |
| SCHEMBL22758079 | 0.73 | EPHX1 (0.52) | EPHX1PDE2ASLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL16633984 | 0.70 | ALDH1A1 (0.43) | EPHX1PDE2ASLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL27985769 | 0.70 | EPHX1 (0.44) | EPHX1SLC6A4SLC6A2ALDH1A1EPHX2 | |
| SCHEMBL27974375 | 0.70 | EPHX2 (0.41) | EPHX1PDE2AALDH1A1EPHX2TRPV1 | |
| SCHEMBL27985768 | 0.70 | EPHX1 (0.44) | EPHX1ALDH1A1EPHX2HRH3 | |
| SCHEMBL27986128 | 0.69 | EPHX1 (0.43) | EPHX1PDE2ASLC6A4SLC6A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | EPHX1 1515/4885PDE2A 1/4885SLC6A4 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.